Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
NCT03960580
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
223
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Rhinosinusitis
Interventions
DRUG:
OPN-375
Sponsor
Optinose US Inc.